ACADIA Pharmaceuticals Inc. (ACAD) Climbed On Phase 2 Study Results

ACADIA Pharmaceuticals Inc. (ACAD) announced Tuesday morning that its Phase 2 study of pimavanserin in patients with Alzheimer's disease psychosis met the primary endpoint.

from RTT - Before the Bell http://ift.tt/2hHbxVi
via IFTTT